Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Binding Ability of Aloe-Emodin to Free l-Cysteine on Hepatic Protein-Induced Hepatocyte Toxicity.

Phytochemical analysis : PCA·2026
Same author

TRIM9 regulates the proliferation and apoptosis of dermal papilla cells by activating the Wnt/β-catenin signaling pathway to improve androgenetic alopecia.

Pathology, research and practice·2026
Same author

Memory-Assisted Nonlocal Interferometer toward Long-Baseline Telescopes.

Physical review letters·2026
Same author

Multi-omics and spatial transcriptomics decode the ZDHHC9-driven hypoxia-immunosuppressive axis in hepatocellular carcinoma.

Frontiers in oncology·2026
Same author

Hyaluronic Acid Hydrogel Inhibits Autophagy Through the miR-181a-5p/ATG5 Molecular Axis to Promote the Adipogenic Differentiation of Adipose-Derived Stem Cells.

Stem cells international·2026
Same author

A Mechanism-Guided Delivery System for Long-Acting Postpartum Depression Therapy via Hydrogen-Facilitated Gut Microbiota Reprogramming.

ACS applied materials & interfaces·2026

Related Experiment Video

Updated: Jul 3, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

H3K27ac-activated LncRNA NUTM2A-AS1 Facilitated the Progression of Colorectal Cancer Cells via MicroRNA-126-5p/FAM3C

Haiguan Lin1,2, Shidong Hu1, Yuxuan Li1

  • 1Department of General Surgery, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.

Current Cancer Drug Targets
|February 13, 2024
PubMed
Summary

Long non-coding RNA NUTM2A-AS1 promotes colorectal cancer (CRC) by increasing FAM3C expression. Silencing this oncogenic lncRNA reduces CRC cell proliferation and enhances apoptosis, offering a potential therapeutic target.

Keywords:
CRCFAM3CH3K27acceRNAlncRNA NUTM2A-AS1miR-126-5ptumor biomarkers.

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.6K
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.1K

Related Experiment Videos

Last Updated: Jul 3, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.6K
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play crucial roles in colorectal cancer (CRC) development.
  • The specific functions of most lncRNAs in CRC remain unclear.

Purpose of the Study:

  • To investigate the role of lncRNA NUTM2A-AS1 in colorectal cancer.
  • To elucidate the molecular mechanisms underlying NUTM2A-AS1's function in CRC.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) for expression analysis.
  • Cell counting kit-8 (CCK-8) and flow cytometry for proliferation and apoptosis assays.
  • Western blot and bioinformatics analyses to identify regulatory pathways.

Main Results:

  • lncRNA NUTM2A-AS1 expression is significantly elevated in CRC cell lines.
  • Silencing NUTM2A-AS1 inhibits CRC cell proliferation and promotes apoptosis.
  • NUTM2A-AS1 upregulates FAM3C by sponging miR-126-5p, and is activated by H3K27ac.

Conclusions:

  • NUTM2A-AS1 functions as an oncogenic lncRNA in CRC.
  • NUTM2A-AS1 promotes CRC malignancy by upregulating FAM3C.
  • NUTM2A-AS1 represents a potential diagnostic and therapeutic target for CRC.